Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints,” extending a ...

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US. The company said the FDA would ...

莫德納 (Moderna) ( MRNA-US) 周五 (10 日) 表示，由於「行政限制」，美國食品和藥物管理局 (FDA) 已將其呼吸道合胞病毒 (RSV) 疫苗的批准順延到 5 月底。

The Food and Drug Administration has pushed back the release of its decision on approval of Moderna’s respiratory syncytial virus vaccine by up to three weeks due to “administrative ...

Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints ...

The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, ...

The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...

Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA has informed it that it will not be able to meet the May 12 PDUFA for their RSV vaccine due to ...

Shares of Ascendis Pharma ASND lost more than 5% on Tuesday after management announced that the FDA extended the review period for its regulatory filing for a hormone replacement therapy by an ...